Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2022-04-21 Proxy Solicitation & In…
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2022
Proxy Solicitation & Information Statement
2022-04-21 English
SC TO-C Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing under Rule 14d-100 of the Securities Exchange Act of 1934, related to a tender offer by Regeneron Pharmaceuticals, Inc. to acquire Checkmate Pharmaceuticals, Inc. It is a formal regulatory filing that communicates preliminary information about the tender offer, including forward-looking statements, instructions on where to find further tender offer materials, and references to future filings such as the Offer to Purchase, Solicitation/Recommendation Statement on Schedule 14D-9, and proxy statements. The document does not contain financial statements or detailed financial results but serves as a regulatory announcement related to a merger and acquisition transaction. Given the nature of the filing as a tender offer statement and preliminary communication before the commencement of the tender offer, the appropriate classification is M&A Activity (TAR).
2022-04-19 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-12 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-11 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-11 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.